secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000914475-23-000023
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine settles INGREZZA patent litigation with Teva; generic entry allowed Feb 2040
--------------------------------------------------------------------------------

- Settlement grants Teva right to sell generic INGREZZA in the U.S. starting February 1, 2040, or earlier under certain conditions.
- Agreement resolves ANDA patent litigation filed in District of Delaware; terms to be submitted to FTC and DOJ.
- Patent litigation against three other ANDA filers for generic INGREZZA remains pending, trial scheduled for January 2, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000023/0000914475-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000023/nbix-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer